HRP20250899T1 - Manitol za uporabu u liječenju hepatotoksičnosti i masnih bolesti jetre - Google Patents

Manitol za uporabu u liječenju hepatotoksičnosti i masnih bolesti jetre

Info

Publication number
HRP20250899T1
HRP20250899T1 HRP20250899TT HRP20250899T HRP20250899T1 HR P20250899 T1 HRP20250899 T1 HR P20250899T1 HR P20250899T T HRP20250899T T HR P20250899TT HR P20250899 T HRP20250899 T HR P20250899T HR P20250899 T1 HRP20250899 T1 HR P20250899T1
Authority
HR
Croatia
Prior art keywords
liver
composition
mannitol
liver disease
fatty liver
Prior art date
Application number
HRP20250899TT
Other languages
English (en)
Croatian (hr)
Inventor
Oliver Yoa-Pu Hu
Tung-Yuan SHIH
Cheng-Huei Hsiong
Hsin-Tien HO
Original Assignee
Sinew Pharma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/CN2016/078039 external-priority patent/WO2017084234A1/zh
Application filed by Sinew Pharma Inc. filed Critical Sinew Pharma Inc.
Publication of HRP20250899T1 publication Critical patent/HRP20250899T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/194Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016Disaccharides, e.g. lactose, lactulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024Esters of saccharides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/16Preparation of carboxylic acids or their salts, halides or anhydrides by oxidation
    • C07C51/21Preparation of carboxylic acids or their salts, halides or anhydrides by oxidation with molecular oxygen
    • C07C51/215Preparation of carboxylic acids or their salts, halides or anhydrides by oxidation with molecular oxygen of saturated hydrocarbyl groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/34Esters of acyclic saturated polycarboxylic acids having an esterified carboxyl group bound to an acyclic carbon atom
    • C07C69/42Glutaric acid esters
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D319/00Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/041,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/061,3-Dioxanes; Hydrogenated 1,3-dioxanes not condensed with other rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00Processes for the preparation of sugar derivatives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/04Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/04Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
    • C07H13/06Fatty acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/428Thiazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004Monosaccharides having only carbon, hydrogen and oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
HRP20250899TT 2015-09-24 2016-09-26 Manitol za uporabu u liječenju hepatotoksičnosti i masnih bolesti jetre HRP20250899T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562222959P 2015-09-24 2015-09-24
US201562257697P 2015-11-19 2015-11-19
PCT/CN2016/078039 WO2017084234A1 (zh) 2015-11-19 2016-03-31 预防或治疗脂肪肝的药物组合物
EP21173210.2A EP3991724B1 (en) 2015-09-24 2016-09-26 Mannitol for use in treating hepatotoxicity and fatty liver diseases

Publications (1)

Publication Number Publication Date
HRP20250899T1 true HRP20250899T1 (hr) 2025-11-07

Family

ID=60047309

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20250899TT HRP20250899T1 (hr) 2015-09-24 2016-09-26 Manitol za uporabu u liječenju hepatotoksičnosti i masnih bolesti jetre

Country Status (20)

Country Link
US (4) US10456371B2 (enExample)
EP (3) EP4609911A3 (enExample)
JP (2) JP2018537517A (enExample)
KR (2) KR20240042148A (enExample)
CN (3) CN107614475A (enExample)
AU (3) AU2016327930B2 (enExample)
BR (1) BR112018005905B1 (enExample)
CA (2) CA2999368A1 (enExample)
EA (1) EA201890810A1 (enExample)
ES (1) ES3044383T3 (enExample)
HK (1) HK1244266A1 (enExample)
HR (1) HRP20250899T1 (enExample)
HU (1) HUE072982T2 (enExample)
MX (2) MX395231B (enExample)
MY (1) MY190647A (enExample)
PH (1) PH12018500659A1 (enExample)
SG (1) SG10202002573RA (enExample)
TW (1) TWI781912B (enExample)
WO (1) WO2017050298A1 (enExample)
ZA (1) ZA201802373B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016520100A (ja) * 2013-11-13 2016-07-11 ▲財▼▲団▼法人国防教育研究基金会National Defense Education And Research Foundation 肝臓に対する副作用がない、新しいアセトアミノフェン複合組成
ES3044383T3 (en) 2015-09-24 2025-11-26 Sinew Pharma Inc Mannitol for use in treating hepatotoxicity and fatty liver diseases
TWI711464B (zh) * 2015-11-19 2020-12-01 欣耀生醫股份有限公司 預防或治療脂肪肝、保護肝功能、或改善脂肪肝引起的肝病變或其他相關病症之組合物及方法
SG11202007314QA (en) * 2018-02-14 2020-08-28 Sinew Pharma Inc Methods and compositions for preventing, reducing or eradicating toxicity caused by acetaminophen (apap)
CN110538187A (zh) * 2018-05-28 2019-12-06 北京大学 Cpt1激活剂
KR102136326B1 (ko) * 2018-09-06 2020-07-22 서울대학교산학협력단 가시박으로부터 분리한 플라보노이드 유도체를 유효성분으로 포함하는 간 질환 예방 또는 치료용 조성물
TWI691719B (zh) * 2018-10-19 2020-04-21 香港商阿瓦隆 海帕波有限公司 半乳糖快速定量檢測系統及其應用
CN109920550A (zh) * 2018-12-25 2019-06-21 天津大学 一种基于dMRI研究青少年肌阵挛性癫痫的方法
AU2020211695A1 (en) * 2019-01-21 2021-09-02 National University Of Singapore Treatment of hepatotoxicity
CN110269855A (zh) * 2019-07-19 2019-09-24 辽宁大学 黄酮类小分子化合物在制备抑制胰脂肪酶活性药物中的应用
US12383191B1 (en) * 2020-05-04 2025-08-12 PathAI, Inc. Systems and methods for assessing liver pathology
CN113999272A (zh) * 2021-10-29 2022-02-01 广西医科大学 香蜂草苷的制备方法及其应用
CN113875982A (zh) * 2021-11-19 2022-01-04 武汉森澜生物科技有限公司 一种含二氢杨梅素的抗衰组合物及其应用
CN117482082A (zh) * 2023-11-27 2024-02-02 西北大学 金松双黄酮在制备抗慢性肾损伤药物中的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4661519A (en) * 1983-04-12 1987-04-28 Pola Chemical Industries Inc. Method for dermatological application
CH664150A5 (de) * 1985-01-15 1988-02-15 Peter Paul Prof Dr Speiser Fumarsaeureprodrug, verfahren zu seiner herstellung und dieses enthaltende darreichungsformen.
JP3916685B2 (ja) * 1996-02-29 2007-05-16 第一製薬株式会社 ガラクトース誘導体
JP4677550B2 (ja) * 2002-08-14 2011-04-27 独立行政法人産業技術総合研究所 環状エステル化合物
TWI287990B (en) * 2004-01-08 2007-10-11 Nat Defense Medical Ct Inhibitors and enhancers of uridine diphosphate-glucuronosyl transferase 2B (UGT2B)
US20070009441A1 (en) * 2004-07-08 2007-01-11 Molecular Therapeutics, Inc. Biodegradable nanoparticles
CN1939929A (zh) * 2005-09-29 2007-04-04 云南白药集团股份有限公司 一种偏诺皂苷类化合物酸式盐及制备方法
CN108465110A (zh) * 2011-04-20 2018-08-31 教育研究基金会 无/低副作用的抗结核病药物复方
US20150291721A1 (en) * 2012-11-12 2015-10-15 Segetis, Inc. Crosslinkable polyketal esters, methods of manufacture and uses thereof
US9211298B2 (en) * 2012-11-16 2015-12-15 Song Gao Compositions containing enriched natural crocin and/or crocetin, and their therapeutic or nutraceutical uses
US9149491B2 (en) * 2013-04-29 2015-10-06 Harsha Chigurupati Reduced toxicity in alcoholic beverages
TWI552748B (zh) 2013-10-25 2016-10-11 The use of a compound for the removal of hepatotoxicity against Acetaminophen (APAP)
CN104623670A (zh) * 2013-11-06 2015-05-20 高松 一种含西红花素的组合物及其应用
JP2016520100A (ja) * 2013-11-13 2016-07-11 ▲財▼▲団▼法人国防教育研究基金会National Defense Education And Research Foundation 肝臓に対する副作用がない、新しいアセトアミノフェン複合組成
CN104292289B (zh) * 2014-07-10 2017-12-29 程怡 半乳糖配体及其在肝靶向脂质体中的应用
ES3044383T3 (en) * 2015-09-24 2025-11-26 Sinew Pharma Inc Mannitol for use in treating hepatotoxicity and fatty liver diseases
TWI711464B (zh) * 2015-11-19 2020-12-01 欣耀生醫股份有限公司 預防或治療脂肪肝、保護肝功能、或改善脂肪肝引起的肝病變或其他相關病症之組合物及方法

Also Published As

Publication number Publication date
EP3991724A3 (en) 2022-07-27
MY190647A (en) 2022-04-30
HUE072982T2 (hu) 2025-12-28
BR112018005905A2 (pt) 2018-10-16
US20240335404A1 (en) 2024-10-10
PH12018500659A1 (en) 2018-10-01
KR20180058795A (ko) 2018-06-01
EA201890810A1 (ru) 2018-11-30
BR112018005905B1 (pt) 2023-03-21
CN107614475A (zh) 2018-01-19
EP3991724A2 (en) 2022-05-04
JP7261850B2 (ja) 2023-04-20
CN120398980A (zh) 2025-08-01
EP4609911A2 (en) 2025-09-03
ES3044383T3 (en) 2025-11-26
EP3991724C0 (en) 2025-07-16
WO2017050298A1 (en) 2017-03-30
US20200009097A1 (en) 2020-01-09
TWI781912B (zh) 2022-11-01
AU2024200963B2 (en) 2026-02-12
MX2018003700A (es) 2018-08-01
KR102891137B1 (ko) 2025-11-25
US20220265587A1 (en) 2022-08-25
CA3232521A1 (en) 2017-03-30
HK1244266A1 (zh) 2018-08-03
TW201722897A (zh) 2017-07-01
MX2022007816A (es) 2022-08-02
CN120349362A (zh) 2025-07-22
AU2024200963A1 (en) 2024-03-07
AU2016327930B2 (en) 2021-04-15
KR20240042148A (ko) 2024-04-01
EP3353144A4 (en) 2019-06-05
AU2021205040B2 (en) 2023-11-16
JP2018537517A (ja) 2018-12-20
JP2022009680A (ja) 2022-01-14
AU2016327930A1 (en) 2018-05-10
EP3353144A1 (en) 2018-08-01
EP3991724B1 (en) 2025-07-16
CA2999368A1 (en) 2017-03-30
US20180256526A1 (en) 2018-09-13
EP4609911A3 (en) 2025-11-19
ZA201802373B (en) 2019-04-24
US10456371B2 (en) 2019-10-29
US11285123B2 (en) 2022-03-29
AU2021205040A1 (en) 2021-08-12
MX395231B (es) 2025-03-25
SG10202002573RA (en) 2020-05-28
US12083088B2 (en) 2024-09-10

Similar Documents

Publication Publication Date Title
DOP2018000182A (es) Benzamidas sustituidas con 1,3–tiazol–2–ilo
BR112018075998A2 (pt) composições antifúngicas sinérgicas e métodos das mesmas
EP3661600A4 (en) FATTY ACID ANALOGS AND ITS USE IN THE TREATMENT OF DISEASES RELATED TO METABOLISM SYNDROME
EP2974598A4 (en) COMPOSITION FOR IMPROVED PLANT PESTICIDAL INJURY OF MONOSACCHARIDE
ITUB20153106A1 (it) Composizione di batteri lattici per uso nel trattamento delle infezioni causate da Propionibacterium acnes e in particolare per l'acne
MY194870A (en) Stuffy nose deblocking composition having antiviral activity
MX2018003700A (es) Compuestos eficaces en el tratamiento de la hepatotoxicidad y enfermedades de higado graso, y uso de los mismos.
HRP20241552T1 (hr) Acetil-leucin ili njegova farmaceutski prihvatljiva sol za poboljšanu pokretljivost
RU2016145066A (ru) Композиция для предотвращения или лечения жировых болезней печени
IL259183B (en) Food supplement and composition for treating the metabolic syndrome
WO2014153009A3 (en) Thiosaccharide mucolytic agents
EP3305301A4 (en) THERAPEUTIC MEANS FOR DRY EYES WITH DROPS LEAVING THE EYE OF A CARRIER OF SOFT CONTACT LENS WITH A DRY EYE
HRP20201221T1 (hr) Sastavi omega 3 masnih kiselina za liječenje bolesti koje uključuju štete nastale u živčanom sustavu
WO2017029558A3 (en) Methods for improving health of farmed fish
JP2014520892A5 (enExample)
HRP20191710T1 (hr) Postupci za liječenje poremećaja ciklusa uree
BR112014004737A2 (pt) composto de composição de cloridrato de ambroxol e método de preparação do composto
JP2014101346A5 (enExample)
BR112015002984A2 (pt) composição, vacina para proteger um animal contra uma infecção com bactérias leptospira, e, uso de ácido cítrico.
EP3338792A4 (en) COMPOSITION FOR THE PREVENTION / TREATMENT OF CORNEAL LESIONS WITH THYMOSINE BETA 4 AND CITRIC ACID AS ACTIVE SUBSTANCES
AR104184A1 (es) Composición pesticida que comprende metomilo y lufenuron
JP2015113322A5 (enExample)
RU2017104518A (ru) Композиция для предупреждения или лечения ожирения, содержащая α-липоевую кислоту и N-ацетилцистеин в качестве активных ингредиентов
HRP20202041T1 (hr) Uporaba otopine etil alkohola u mekanim pekarskim proizvodima
EP3419604A4 (en) IMPROVED FORMULATION OF A LONG-ACTING INJECTABLE DEPOTSUSPENSION OF LEVONORGESTRELBUTANOAT